Top Tweets for #CTAD2017
#CTADconference #CTAD17 #CTAD2017 Break out the boots! Walking boosts thinking - especially in #amyloid-positive subjects.
https://t.co/7CQKTVGg0r
#CTAD17 #CTAD2017
All our @CTADconference stories here... Keep watching! Up next: tau PET predicts cognitive change in normal pts. Do retinal changes signal preclinical #Alzheimers? And, the unfolded protein response -what is it and why should we care?
https://t.co/iLtxSvlTjl
Long-term cholinesterase inhibition may slow cognitive decline – and more. #CTAD2017 https://t.co/uoDLaFX1bb
Long-term cholinesterase inhibition may slow cognitive decline – and more. #CTAD2017 https://t.co/F9Ids5vSX3
Long-term cholinesterase inhibition may slow cognitive decline – and more. #CTAD2017 https://t.co/UczIOrzjBT
#CTAD17 #CTAD2017 #Merck's data dive: BACE inhibitor #verubecestat was completely ineffective in mild-moderate #Alzheimers
https://t.co/k7vLzBm6Ol
Al Sandrock, EVP & CMO, discusses Biogen’s commitment to Alzheimer's disease research #CTAD2017
Reflecting post #CTAD2017 on interesting emerging evidence
on role of #Inflammatory pathways in #dementia therapeutics. RAGE inhibitor
#Azeliragon Phase 2 results - now in Phase 3 trials -CB
Check out NCT’s latest #cognitive research & #eCOAs featured at this year’s @CTADconference #ctad17 #CTAD2017 https://t.co/K9MB1RRZUR
Aducanumab probably has the best named trials in #Alzheimers disease. 36-month data from the PRIME study from #CTAD2017. No new safety signals identified. Awaiting results from ENGAGE and EMERGE. $BIIB
ALZ-801, pro-drug of tramiprosate, in #Alzheimers disease at #CTAD2017. Largest benefit in a subgroup (North America) within a subgroup (APOE4/E4) within a subgroup (MMSE >22). Proposed MoA convincing. Magnitude of clinical benefit likely exaggerated. #Alzheon
NILVAD trial - Phase 3 study of nilvadipine in #Alzheimer's disease failed to find benefit on co-primary or secondary endpoints. Benefit found in subgroup with higher MMSE...sound familiar? #CTAD2017
Discussion of Phase 2 trial involving pimavanserin in #Alzheimer's disease psychosis at #CTAD2017. Approved for Parkinson's disease psychosis. Still has black box warning for increased mortality. $ACAD https://t.co/Ow6LH7tqfA
Samantha Budd Haeberlein, VP, Clinical Development discusses Alzheimer’s disease research #CTAD2017
Nice summary of #CTAD2017 and the current state of Alzheimer's research by @damiangarde https://t.co/N539YOLFan
The upside of down: Notes from a hesitantly hopeful Alzheimer’s conference 🔒https://t.co/wVBGO6vniz
Dr. Boada @FundacioACE @CTADconference : “We need to shift the paradigm and detect #dementia BEFORE symptoms appear.” #CTAD2017
#CTAD2017
3 fármacos en ensayo clínico para el #Alzheimer a los que seguir de cerca https://t.co/mlxqmTTB4o
Return to UK after #CTAD2017 - recent trial failures announced and future promise - #learnfrommistakes = @IMI_EPAD better design & delivery
Last Seen Hashtags on Sotwe
Most Popular Users
Elon Musk 
@elonmusk
241.5M followers
Barack Obama
@barackobama
119M followers
Cristiano Ronaldo
@cristiano
114M followers
Donald J. Trump
@realdonaldtrump
111.8M followers
Narendra Modi
@narendramodi
107.2M followers
Rihanna
@rihanna
98.6M followers
NASA
@nasa
92.4M followers
Justin Bieber
@justinbieber
91.8M followers
KATY PERRY
@katyperry
89.8M followers
Taylor Swift
@taylorswift13
83.7M followers
Lady Gaga
@ladygaga
75.2M followers
Virat Kohli
@imvkohli
72.9M followers
Kim Kardashian
@kimkardashian
70.8M followers
YouTube
@youtube
68.8M followers
Neymar Jr
@neymarjr
65.9M followers
Bill Gates
@billgates
64.9M followers
Selena Gomez
@selenagomez
62.8M followers
The Ellen Show
@theellenshow
62.3M followers
CNN
@cnn
61.8M followers
X
@x
60.7M followers